Terms: = Lung cancer AND HOXD13, SPD, 3239, P35453, HOX4I AND Prognosis
30 results:
1. Soluble programmed death ligand 1 as prognostic biomarker in non-small cell lung cancer patients receiving nivolumab, pembrolizumab or atezolizumab therapy.
Brun SS; Hansen TF; Wen SWC; Nyhus CH; Bertelsen L; Jakobsen A; Hansen TS; Nederby L
Sci Rep; 2024 Apr; 14(1):8993. PubMed ID: 38637655
[TBL] [Abstract] [Full Text] [Related]
2. The Expression and Prognostic Significance of ICOS in NSCLC Integrated Pan-cancer and Multi-Omics Analyses.
Chen M; Yan X; Hong B; Xiao Y; Qian Y
Int J Med Sci; 2024; 21(5):795-808. PubMed ID: 38616999
[No Abstract] [Full Text] [Related]
3. Plasma spd-L1 and VEGF levels are associated with the prognosis of NSCLC patients treated with combination immunotherapy.
Dong C; Hui K; Gu J; Wang M; Hu C; Jiang X
Anticancer Drugs; 2024 Jun; 35(5):418-425. PubMed ID: 38386011
[TBL] [Abstract] [Full Text] [Related]
4. spd-L1 and spd-L2 in plasma of patients with lung cancer and their clinical significance.
Han S; Zhang Y; Yuan J; Wu Y; Zhou Y; Zhou Y; Li X; Zhou S
Cytokine; 2024 Apr; 176():156532. PubMed ID: 38330638
[TBL] [Abstract] [Full Text] [Related]
5. Soluble PD-L1 changes in advanced non-small cell lung cancer patients treated with PD-1 inhibitors: an individual patient data meta-analysis.
Shimizu T; Inoue E; Ohkuma R; Kobayashi S; Tsunoda T; Wada S
Front Immunol; 2023; 14():1308381. PubMed ID: 38115995
[TBL] [Abstract] [Full Text] [Related]
6. Prognostic significance of blood-based PD-L1 analysis in patients with non-small cell lung cancer undergoing immune checkpoint inhibitor therapy: a systematic review and meta-analysis.
Cui Q; Li W; Wang D; Wang S; Yu J
World J Surg Oncol; 2023 Oct; 21(1):318. PubMed ID: 37821941
[TBL] [Abstract] [Full Text] [Related]
7. Analysis of soluble programmed death-1 ligand-1 of lung cancer patients with different characteristics.
Zhu HB; Song X
Eur Rev Med Pharmacol Sci; 2023 Sep; 27(18):8690-8696. PubMed ID: 37782182
[TBL] [Abstract] [Full Text] [Related]
8. Subcutaneous Leiomyosarcoma: An Aggressive Malignancy Portending a Significant Risk of Metastasis and Death.
Bresler SC; Gosnell HL; Ko JS; Angeles CV; Ronen S; Billings SD; Patel RM
Am J Surg Pathol; 2023 Dec; 47(12):1417-1424. PubMed ID: 37727934
[TBL] [Abstract] [Full Text] [Related]
9. Prognostic impact of soluble PD-L1 derived from tumor-associated macrophages in non-small-cell lung cancer.
Teramoto K; Igarashi T; Kataoka Y; Ishida M; Hanaoka J; Sumimoto H; Daigo Y
Cancer Immunol Immunother; 2023 Nov; 72(11):3755-3764. PubMed ID: 37646826
[TBL] [Abstract] [Full Text] [Related]
10. Hyperthermic intrathoracic extracorporeal chemotherapy for secondary malignant pleural disease.
Miller DL; Parks CS; Ange B; Bonta IR; Rich PT
J Surg Oncol; 2023 Sep; 128(4):604-611. PubMed ID: 37409778
[TBL] [Abstract] [Full Text] [Related]
11. Clinical roles of soluble PD-1 and PD-L1 in plasma of NSCLC patients treated with immune checkpoint inhibitors.
Himuro H; Nakahara Y; Igarashi Y; Kouro T; Higashijima N; Matsuo N; Murakami S; Wei F; Horaguchi S; Tsuji K; Mano Y; Saito H; Azuma K; Sasada T
Cancer Immunol Immunother; 2023 Aug; 72(8):2829-2840. PubMed ID: 37188764
[TBL] [Abstract] [Full Text] [Related]
12. Meta-analysis of the prognostic value of soluble programmed death ligand-1 (spd-L1) in cancers.
Sun J; Hu S; Li X
Biomarkers; 2023 Sep; 28(6):477-485. PubMed ID: 37017446
[TBL] [Abstract] [Full Text] [Related]
13. Prognostic Role of Soluble and Extracellular Vesicle-Associated PD-L1, B7-H3 and B7-H4 in Non-Small Cell lung cancer Patients Treated with Immune Checkpoint Inhibitors.
Genova C; Tasso R; Rosa A; Rossi G; Reverberi D; Fontana V; Marconi S; Croce M; Dal Bello MG; Dellepiane C; Tagliamento M; Ciferri MC; Zullo L; Fedeli A; Alama A; Cortese K; Gentili C; Cella E; Anselmi G; Mora M; Barletta G; Rijavec E; Grossi F; Pronzato P; Coco S
Cells; 2023 Mar; 12(6):. PubMed ID: 36980174
[TBL] [Abstract] [Full Text] [Related]
14. Immune infiltration landscape on prognosis and therapeutic response and relevant epigenetic and transcriptomic mechanisms in lung adenocarcinoma.
Zhang L; Jiang B; Lan Z; Yang C; Yao Y; Lin J; Wei Q
Front Immunol; 2022; 13():983570. PubMed ID: 36275753
[TBL] [Abstract] [Full Text] [Related]
15. Prognostic value of soluble programmed cell death ligand-1 in patients with non-small-cell lung cancer: a meta-analysis.
Wang Y; He H
Immunotherapy; 2022 Aug; 14(12):945-956. PubMed ID: 35822688
[No Abstract] [Full Text] [Related]
16. Soluble PD-L1 is a predictive and prognostic biomarker in advanced cancer patients who receive immune checkpoint blockade treatment.
Oh SY; Kim S; Keam B; Kim TM; Kim DW; Heo DS
Sci Rep; 2021 Oct; 11(1):19712. PubMed ID: 34611279
[TBL] [Abstract] [Full Text] [Related]
17. Characterization of soluble PD-L1 in pleural effusions of mesothelioma patients: potential implications in the immune response and prognosis.
Carosio R; Fontana V; Mastracci L; Ferro P; Grillo F; Banelli B; Canessa PA; Dessanti P; Vigani A; Morabito A; Pfeffer U; Poggi A; Roncella S; Pistillo MP
J Cancer Res Clin Oncol; 2021 Feb; 147(2):459-468. PubMed ID: 33216211
[TBL] [Abstract] [Full Text] [Related]
18. Association between serum level soluble programmed cell death ligand 1 and prognosis in patients with non-small cell lung cancer treated with anti-PD-1 antibody.
Murakami S; Shibaki R; Matsumoto Y; Yoshida T; Goto Y; Kanda S; Horinouchi H; Fujiwara Y; Yamamoto N; Ohe Y
Thorac Cancer; 2020 Dec; 11(12):3585-3595. PubMed ID: 33108686
[TBL] [Abstract] [Full Text] [Related]
19. Platelet factor 4 regulates T cell effector functions in malignant pleural effusions.
Mulet M; Zamora C; Porcel JM; Nieto JC; Pajares V; Muñoz-Fernandez AM; Calvo N; Esquerda A; Vidal S
Cancer Lett; 2020 Oct; 491():78-86. PubMed ID: 32726613
[TBL] [Abstract] [Full Text] [Related]
20. Study on the Expression Levels and Clinical Significance of PD-1 and PD-L1 in Plasma of NSCLC Patients.
He J; Pan Y; Guo Y; Li B; Tang Y
J Immunother; 2020 Jun; 43(5):156-164. PubMed ID: 32168233
[TBL] [Abstract] [Full Text] [Related]
[Next]